[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642258":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":32,"locations":38,"responsibleParty":77,"collaborators":10,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":10,"maxAge":86,"enrollmentInfo":87,"targetDuration":90,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"MuseCell Innovations Pte LTD","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Orthopaedic",null,"Patients undergoing treatment for orthopaedic conditions",[13],"Other: MuseCell Treatment",{"label":15,"type":10,"description":16,"interventionNames":17},"Longevity","Patients undergoing treatment for longevity and inflammation",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Wound Care","Patients undergoing treatment to treat wounds",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Pain","Patients undergoing treatment for various pain conditions",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"OTHER","MuseCell Treatment","Patients undergoing treatment with Dezawa MuseCells",[15,9,23,19],[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"MuseCell Information","CONTACT","+65 80166929","info@musecellinnovations.com",[39,63],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Bioreset Medical","RECRUITING","North Palm Beach","Florida","33408","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-80.08199,26.81756,{"lat":51,"lon":50},[54,58,61],{"name":55,"role":35,"phone":56,"phoneExt":10,"email":57},"Jeffrey Wiegers, MD","650- 888-7950","Info@bioresetmedical.com",{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Matt Cook, MD","SUB_INVESTIGATOR",{"name":55,"role":62,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":64,"status":41,"city":65,"state":10,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Regene Labs","Guadalajara","Mexico","MX",{"type":48,"coordinates":69},[70,71],-103.34749,20.67738,{"lat":71,"lon":70},[74],{"name":64,"role":35,"phone":75,"phoneExt":10,"email":76},"+523327840019","contacto@regeneglobal.com",{"type":78,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642258","registry-of-outcomes-of-dezawa-musecells-100642258",false,"NCT07645989","Registry of Outcomes of Dezawa MuseCells®","Inclusion Criteria:\n\n1. Received Dezawa MuseCells® as Part of Routine Clinical Care\n2. Patients ( and\u002For authorized representative) capable of providing informed consent and participating in long-term follow-up.\n3. Willingness to Complete Online Survey Assessments\n4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.\n5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.\n6. Ability to Communicate in the Registry's Supported Language\n7. Participants must be able to read and respond to registry surveys in the designated study language.\n8. Enrollment Within 12 Months of MuseCell® Administration\n\nExclusion Criteria:\n\n1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit\u002Fnon-licensed product cannot be included.\n2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.\n3. Inability to Participate in Long-Term Digital Follow-Up\n4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes\n5. History of Malignancy Diagnosed Within the Past 12 Months\n6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.\n7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality\n8. Use of Non-Licensed or Counterfeit \"Muse-like\" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.\n9. Pregnant or Actively Breastfeeding at Time of Enrollment","ALL","89 Years",{"count":88,"type":89},5000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.\n\nThe Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.",[94,15,19,23,9],"Osteoarthritis (OA)",[96,97,98,99,100],"Muse Cells","stem cells","pain","wound","inflammation","2026-06-11",{"date":103,"type":104},"2026-06-12","ACTUAL",{"date":106,"type":89},"2026-07-01",{"date":108,"type":89},"2031-12-31",{"name":5,"class":6},2]